Search Result
Results for "
carrier peptide
" in MedChemExpress (MCE) Product Catalog:
12
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B2247A
-
|
poly(lactic-co-glycolic acid) (75:25)
|
Biochemical Assay Reagents
|
Others
|
|
PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .
|
-
-
- HY-142104
-
|
2-Chlorotrityl Chloride Resin (100-200 mesh,1% DVB,0.4-3.0mmol/g)
|
Drug Intermediate
|
Cancer
|
|
2-CTC Resin (100-200 mesh,1% DVB,0.4-3.0mmol/g) is a solid-phase synthesis carrier that has been used to study metabolic disorders in prostate cancer cells. 2-CTC Resin (100-200 mesh,1% DVB,0.4-3.0mmol/g) can be used as a reaction solution of terminal residues and adenine nucleotides to form cyclic peptides. 2-CTC Resin (100-200 mesh,1% DVB,0.4-3.0mmol/g) can prevent racemization during the incorporation of the first protected amino acid and minimized diketopiperazine formation. 2-CTC Resin (100-200 mesh,1% DVB,0.4-3.0mmol/g) is one of the most commonly used and versatile resins available for large-scale production of peptides .
|
-
-
- HY-P10709
-
|
|
Collagen
|
Cardiovascular Disease
Cancer
|
|
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .
|
-
-
- HY-P10128
-
-
-
- HY-149449
-
|
|
Amino Acid Derivatives
|
Cancer
|
|
Poly-L-γ-glutamic acid sodium is a macromolecular polymer formed by the linkage of glutamic acid residues via peptide bonds between γ-amino and carboxyl groups. Poly-L-γ-glutamic acid sodium plays an important role as a carrier material in compound delivery systems. Poly-L-γ-glutamic acid sodium can deliver Paclitaxel (HY-B0015) to colon cancer cells, reduce cell viability and inhibit the growth of colon cancer spheroids. Poly-L-γ-glutamic acid sodium can be used as a carrier material and in studies related to colon cancer in mice .
|
-
-
- HY-172470
-
|
|
Liposome
EGFR
|
Cancer
|
|
DSPE-PEG2000-GE11 is a nanocarrier component composed of DSPE and the EGFR-targeting peptide (GE11). DSPE-PEG2000-GE11 specifically binds to EGFR and mediates receptor-mediated endocytosis of micellar drug carriers. DSPE-PEG2000-GE11 can be used for drug delivery .
|
-
-
- HY-P10502
-
|
|
LDLR
|
Infection
|
|
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC50 of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery .
|
-
-
- HY-P6022
-
|
|
Integrin
|
Others
|
|
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology
|
-
-
- HY-P3436
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
-
- HY-P10502A
-
|
|
LDLR
|
Others
|
|
L57 acetate is a Low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 acetate exhibits high affinity to LRP1 with Ki of 45 nM. L57 acetate exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 acetate can be utilized as the carrier for CNS drug delivery .
|
-
-
- HY-P4123
-
|
|
MMP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
TAT (47-57) GGG-Cys (Npys) is a cell-penetrating peptide and delivery carrier derived from TAT. TAT (47-57) GGG-Cys (Npys) facilitates the translocation of conjugated drug molecules across cell membranes. TAT (47-57) GGG-Cys (Npys) acts as a delivery carrier for MT1-MMP inhibitors. TAT (47-57) GGG-Cys (Npys) is applicable to research on diseases associated with MT1-MMP activity, such as cancer, arthritis, heart disease, and vascular disorders .
|
-
-
- HY-P10501A
-
|
|
Antifolate
|
Cancer
|
|
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .
|
-
-
- HY-W012166
-
|
NHS-Bromoacetate
|
Biochemical Assay Reagents
|
Infection
|
|
N-Succinimidyl bromoacetate (NHS-Bromoacetate) is a heterobifunctional crosslinking reagent, mainly used to modify the ɛ-amino group of lysine side chains. By covalently linking its bromoacetyl moiety to the ɛ-amino group of lysine in peptidomimetics, N-Succinimidyl bromoacetate enables their conjugation with thiol-modified nanoparticles via thioether bonds. N-Succinimidyl bromoacetate also performs bromoacetylation modification on carrier proteins, which then forms stable thioether bonds with the thiol groups of cysteine in peptides, thus efficiently preparing soluble peptide-protein conjugates with high substitution ratios. N-Succinimidyl bromoacetate can be used to prepare activated Sepharose derivatives for affinity chromatography, protein affinity labeling reagents, and peptide-protein immunogen conjugates with non-immunogenic linkages. N-Succinimidyl bromoacetate is applicable to studies related to HIV-1 infection and glioblastoma multiforme .
|
-
-
- HY-P5107
-
|
LMWP; TDSP5
|
VEGFR
|
Cancer
|
|
Low molecular weight protamine (LMWP;TDSP5) is a truncated arginine-rich protamine peptide, as well as a heparin/low-molecular-weight heparin antidote and a cell-penetrating delivery carrier. Low molecular weight protamine neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities, and also neutralizes anti-Xa activity of commercially available low-molecular-weight heparin preparations. Low molecular weight protamine translocates across mammalian cell membranes, delivers conjugated impermeable molecules across tumor tissues, enhances skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine can be used in studies related to colon adenocarcinoma, skin wounds and diabetic skin wounds .
|
-
-
- HY-W010756
-
|
|
Biochemical Assay Reagents
|
Others
|
|
FMOC-AM is a derivative of aminomethyl resin. FMOC-AM provides a solid-phase carrier basis for peptide chain synthesis and can be used in solid-phase peptide synthesis .
|
-
-
- HY-P4205
-
|
|
Aminopeptidase
|
Cancer
|
|
Aminopeptidase N Ligand (CD13) NGR peptide is a polypeptide targeting CD13 and can be used as a carrier to mediate intracellular transmission. Aminopeptidase N Ligand (CD13) NGR peptide is often used in cancer research .
|
-
-
- HY-P10501
-
|
|
Antifolate
|
Cancer
|
|
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .
|
-
-
- HY-P10786
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .
|
-
-
- HY-113225B
-
|
GTP tritris
|
Endogenous Metabolite
Exosomes
|
Cancer
|
|
Guanosine triphosphate tritris (GTP tritris) serves as a vital enhancer of myogenic cell differentiation and plays a critical role in modulating miRNA-myogenic regulator factors. It also facilitates the release of exosomes enriched with guanosine and guanosine-derived molecules, and is regarded as an activated precursor for RNA synthesis. In mitochondrial function, GTP participates in the import of proteins into the matrix, which is essential for various regulated pathways, and is involved in initiating peptide synthesis through the binding of formylmethionyl-tRNA to the ribosome, as well as polypeptide chain elongation. Additionally, GTP acts as a phosphate and pyrophosphate carrier that channels chemical energy into specific biosynthetic pathways. It activates signal transducing G proteins that regulate cellular processes such as proliferation and differentiation, and its hydrolysis by small GTPases, including Ras and Rho, is integral to both proliferation and apoptosis. Furthermore, the small GTPase Rab is instrumental in vesicle docking, fusion, and formation. Beyond signal transduction, GTP is an energy-rich precursor in the enzymatic biosynthesis of DNA and RNA.
|
-
-
- HY-P10157
-
|
|
Biochemical Assay Reagents
|
Others
|
|
ARF(1-22) is potentially capable of intracellular penetration to deliver small molecules, proteins, imaging agents, and pharmaceutical nanocarriers .
|
-
-
- HY-P2853A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Hemocyanin-SMCC is a hemocyanin that can be used as a carrier protein to couple low molecular weight molecules such as peptides, nucleic acids, drugs or toxins to make them highly immunogenic.
|
-
-
- HY-160473A
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
TAM557 TFA is a cytotoxic tubulysin compounds, which is modified to be used for conjugation to transport vehicles that are targeting molecules, such as proteins, peptides, small molecules or polymeric carriers which can carry a targeting principle .
|
-
-
- HY-P3436A
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW TFA is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW TFA can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
-
- HY-P5439
-
|
|
PKC
MARCKS
|
Others
|
|
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
|
-
-
- HY-P11301
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
Cancer
|
|
C16-pHD108 is a pH-responsive nanopore-forming peptide. C16-pHD108 functions as a macromolecule delivery carrier via endosomal membrane nanoporation. C16-pHD108 is promising for research of cancers and neurodegenerative diseases .
|
-
-
- HY-203300D
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOPE-PEG1000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG1000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
-
- HY-203300C
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOPE-PEG5000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG5000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
-
- HY-203300B
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOPE-PEG3400-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG3400-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
-
- HY-203300A
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOPE-PEG1000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG1000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
-
- HY-203300
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DOPE-PEG2000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG2000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
-
- HY-P11733
-
|
|
Bacterial
|
Infection
|
(KFF)3K-acpP is an antibacterial agent conjugating of cell penetrating peptide (KFF)3K (HY-P10556) and acpP
peptide nucleic acid. (KFF)3K-acpP binds to the translation start site region of acpP mRNA, sterically blocking ribosome binding and inhibiting translation of the acyl carrier protein. (KFF)3K-acpP induces bacterial envelope stress response pathways, and triggers depletion of outer membrane protein F (ompF) transcript. (KFF)3K-acpP can be used for the research of infections .
|
-
-
- HY-182094C
-
|
|
Liposome
|
Metabolic Disease
|
|
DSPE-PEG5000-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG5000-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
-
-
- HY-182094
-
|
|
Liposome
|
Metabolic Disease
|
|
DSPE-PEG1000-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG1000-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
-
-
- HY-182094A
-
|
|
Liposome
|
Metabolic Disease
|
|
DSPE-PEG2000-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG2000-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
-
-
- HY-182094B
-
|
|
Liposome
|
Metabolic Disease
|
|
DSPE-PEG3400-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG3400-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
-
-
- HY-P11612
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
ATS-9R is a peptide consisting of an adipocyte-targeting sequence and D-form 9-arginine. ATS-9R selectively transfects mature adipocytes by binding to prohibitin. ATS-9R allows an adipocyte-targeted gene delivery in vitro and in vivo. ATS-9R can be used for the development of an adipocyte-targeted gene carrier. ATS-9R can be used for the study of obesity as well as obesity-induced metabolic syndromes .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-149449
-
|
|
Biochemical Assay Reagents
|
|
Poly-L-γ-glutamic acid sodium is a macromolecular polymer formed by the linkage of glutamic acid residues via peptide bonds between γ-amino and carboxyl groups. Poly-L-γ-glutamic acid sodium plays an important role as a carrier material in compound delivery systems. Poly-L-γ-glutamic acid sodium can deliver Paclitaxel (HY-B0015) to colon cancer cells, reduce cell viability and inhibit the growth of colon cancer spheroids. Poly-L-γ-glutamic acid sodium can be used as a carrier material and in studies related to colon cancer in mice .
|
-
- HY-172470
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-GE11 is a nanocarrier component composed of DSPE and the EGFR-targeting peptide (GE11). DSPE-PEG2000-GE11 specifically binds to EGFR and mediates receptor-mediated endocytosis of micellar drug carriers. DSPE-PEG2000-GE11 can be used for drug delivery .
|
-
- HY-P2853A
-
|
|
Biochemical Assay Reagents
|
|
Hemocyanin-SMCC is a hemocyanin that can be used as a carrier protein to couple low molecular weight molecules such as peptides, nucleic acids, drugs or toxins to make them highly immunogenic.
|
-
- HY-203300D
-
|
|
Biochemical Assay Reagents
|
|
DOPE-PEG1000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG1000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
- HY-203300C
-
|
|
Biochemical Assay Reagents
|
|
DOPE-PEG5000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG5000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
- HY-203300B
-
|
|
Biochemical Assay Reagents
|
|
DOPE-PEG3400-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG3400-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
- HY-203300A
-
|
|
Biochemical Assay Reagents
|
|
DOPE-PEG1000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG1000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
- HY-203300
-
|
|
Biochemical Assay Reagents
|
|
DOPE-PEG2000-NHS is a conjugate composed of DOPE, PEG chains, and terminal active ester (NHS). The NHS ester in DOPE-PEG2000-NHS can rapidly covalently react with molecules containing primary amines (such as proteins, peptide chains, and small molecules modified with amino groups) to form stable amide bonds, suitable for the construction of carriers requiring membrane fusion properties or pH-sensitive release (such as gene delivery systems).
|
-
- HY-182094C
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG5000-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG5000-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
-
- HY-182094
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG1000-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG1000-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
-
- HY-182094A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG2000-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
-
- HY-182094B
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG3400-KTP is a PEG compound which composed of DSPE and a Kidney-targeting peptide KTP (HY-P11069). KTP can interact with specific proteins on the surface of renal tubular epithelial cells or exhibit higher affinity in the specific renal microenvironment, tending to aggregate or be internalized within the renal tubular epithelium. DSPE-PEG3400-KTP can actively guide carriers such as nanomedicines, liposomes, and microspheres to the kidney .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10709
-
|
|
Collagen
|
Cardiovascular Disease
Cancer
|
|
CREKA peptide is a selective non-covalent binding agent targeting fibrin, type IV collagen, and fibronectin, often used as a targeting ligand to modify delivery carriers. CREKA peptide specifically recognizes fibrin, fibronectin, and type IV collagen that are excessively deposited in the tumor microenvironment or fibrotic tissue, mediating the targeted accumulation of the carrier at the lesion site and promoting drug internalization into target cells (such as cancer cells and activated hepatic stellate cells). CREKA peptide can enhance targeted delivery efficiency, increase drug concentration at the lesion site, and reduce systemic side effects .
|
-
- HY-P10128
-
-
- HY-P10502
-
|
|
LDLR
|
Infection
|
|
L57 is a low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 exhibits high affinity for LRP1, with an EC50 of 45 nM. L57 possesses blood-brain barrier (BBB) permeability and plasma stability. L57 can serve as a carrier for central nervous system drug delivery .
|
-
- HY-P6022
-
|
|
Integrin
|
Others
|
|
G4RGDSP, Integrin-binding peptide is a cell integrin-binding peptide that targets integrin receptors. G4RGDSP, integrin-binding peptide is coupled to alginate to increase the viability of cells in the scaffold. G4RGDSP, integrin-binding peptide can be used as an extrudable carrier for chondrocyte delivery for the study of 3D printing technology
|
-
- HY-P3436
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
- HY-113003
-
|
γ-Glutamylglutamine; γ-Glu-Gln
|
Peptides
|
Others
Cancer
|
|
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .
|
-
- HY-P10502A
-
|
|
LDLR
|
Others
|
|
L57 acetate is a Low-density lipoprotein receptor-related protein 1 (LRP1)-binding peptide. L57 acetate exhibits high affinity to LRP1 with Ki of 45 nM. L57 acetate exhibits blood-brain barrier (BBB) permeability and plasma stability. L57 acetate can be utilized as the carrier for CNS drug delivery .
|
-
- HY-P4104
-
|
|
Peptides
|
Others
|
|
pVEC (Cadherin-5) is a cell-penetrating 18-amino acid-long peptide derived from the murine sequence of the cell adhesion molecule vascular endothelial cadherin. pVEC (Cadherin-5) is efficiently and rapidly taken up into cells, it can be used as a carrier peptide .
|
-
- HY-P4123
-
|
|
MMP
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
TAT (47-57) GGG-Cys (Npys) is a cell-penetrating peptide and delivery carrier derived from TAT. TAT (47-57) GGG-Cys (Npys) facilitates the translocation of conjugated drug molecules across cell membranes. TAT (47-57) GGG-Cys (Npys) acts as a delivery carrier for MT1-MMP inhibitors. TAT (47-57) GGG-Cys (Npys) is applicable to research on diseases associated with MT1-MMP activity, such as cancer, arthritis, heart disease, and vascular disorders .
|
-
- HY-P10501A
-
|
|
Antifolate
|
Cancer
|
|
FRα-targeting peptide C7 TFA is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 TFA can be used in the research of tumor diagnosis and treatment .
|
-
- HY-P5107
-
|
LMWP; TDSP5
|
VEGFR
|
Cancer
|
|
Low molecular weight protamine (LMWP;TDSP5) is a truncated arginine-rich protamine peptide, as well as a heparin/low-molecular-weight heparin antidote and a cell-penetrating delivery carrier. Low molecular weight protamine neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities, and also neutralizes anti-Xa activity of commercially available low-molecular-weight heparin preparations. Low molecular weight protamine translocates across mammalian cell membranes, delivers conjugated impermeable molecules across tumor tissues, enhances skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine can be used in studies related to colon adenocarcinoma, skin wounds and diabetic skin wounds .
|
-
- HY-P4080
-
|
|
Peptides
|
Others
|
|
MPG peptides, Pα is an amphipathic carrier peptide that can be used for drug delivery .
|
-
- HY-P4205
-
|
|
Aminopeptidase
|
Cancer
|
|
Aminopeptidase N Ligand (CD13) NGR peptide is a polypeptide targeting CD13 and can be used as a carrier to mediate intracellular transmission. Aminopeptidase N Ligand (CD13) NGR peptide is often used in cancer research .
|
-
- HY-P10501
-
|
|
Antifolate
|
Cancer
|
|
FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .
|
-
- HY-P10786
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
LinTT1 peptide is a tumor-penetrating peptide with the amino acid sequence AKRGARST. LinTT1 peptide targets peritoneal carcinoma (PC) by binding to the p32 (gC1qR) receptor. It can conjugate with iron oxide nanoworms (NWs) to form a nanocarrier. This nanocarrier is taken up by peritoneal carcinoma cells in vitro and enters the mitochondria; it also exhibits significant tumor targeting and penetration effects in mice. Moreover, LinTT1-functionalized nanocarriers, combined with the pro-apoptotic peptide [D(KLAKLAK)2], show significant tumor suppression in a mouse peritoneal tumor model. LinTT1 peptide holds promise as a delivery carrier for peritoneal cancer research .
|
-
- HY-P10157
-
|
|
Biochemical Assay Reagents
|
Others
|
|
ARF(1-22) is potentially capable of intracellular penetration to deliver small molecules, proteins, imaging agents, and pharmaceutical nanocarriers .
|
-
- HY-P3436A
-
|
|
Exosomes
|
Cardiovascular Disease
|
|
WLSEAGPVVTVRALRGTGSW TFA is a cardiomyocyte-targeting peptide that specifically recognizes tenascin X on the surface of cardiomyocytes. WLSEAGPVVTVRALRGTGSW TFA can serve as a targeting ligand to conjugate with various therapeutic carriers (drugs, genes, exosomes, nanoparticles, etc.) for research on cardiovascular diseases (such as myocardial infarction, heart failure) .
|
-
- HY-P5439
-
|
|
PKC
MARCKS
|
Others
|
|
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
|
-
- HY-P11301
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
Cancer
|
|
C16-pHD108 is a pH-responsive nanopore-forming peptide. C16-pHD108 functions as a macromolecule delivery carrier via endosomal membrane nanoporation. C16-pHD108 is promising for research of cancers and neurodegenerative diseases .
|
-
- HY-P11733
-
|
|
Bacterial
|
Infection
|
(KFF)3K-acpP is an antibacterial agent conjugating of cell penetrating peptide (KFF)3K (HY-P10556) and acpP
peptide nucleic acid. (KFF)3K-acpP binds to the translation start site region of acpP mRNA, sterically blocking ribosome binding and inhibiting translation of the acyl carrier protein. (KFF)3K-acpP induces bacterial envelope stress response pathways, and triggers depletion of outer membrane protein F (ompF) transcript. (KFF)3K-acpP can be used for the research of infections .
|
-
- HY-P11612
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
ATS-9R is a peptide consisting of an adipocyte-targeting sequence and D-form 9-arginine. ATS-9R selectively transfects mature adipocytes by binding to prohibitin. ATS-9R allows an adipocyte-targeted gene delivery in vitro and in vivo. ATS-9R can be used for the development of an adipocyte-targeted gene carrier. ATS-9R can be used for the study of obesity as well as obesity-induced metabolic syndromes .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Compare |
Product Name |
Species |
Source |
Image |
Compare Products
|
| Products |
|
| Cat. No. |
|
| Species |
|
| Source |
|
| Tag |
|
| Accession |
|
| Gene ID |
|
| Molecular Weight |
|
| Purity |
|
| Endotoxin Level |
|
| Biological Activity |
|
| Appearance |
|
| Formulation |
|
| Storage & Stability |
|
| Shipping |
|
| Free Sample |
Yes
No
|
| Size |
* This product has been "discontinued".
Optimized version of product available:
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-B2247A
-
|
poly(lactic-co-glycolic acid) (75:25)
|
|
Polymers
|
|
PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .
|
-
- HY-172470
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-GE11 is a nanocarrier component composed of DSPE and the EGFR-targeting peptide (GE11). DSPE-PEG2000-GE11 specifically binds to EGFR and mediates receptor-mediated endocytosis of micellar drug carriers. DSPE-PEG2000-GE11 can be used for drug delivery .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
